[Long-term results of chemoembolization of primary liver cancer with epirubicin-lipiodol].

This pilot study deals with the long-term results from lipiodol-epirubicin chemo-embolisation in 25 patients with hepatocellular or cholangiocellular carcinomas. In a three-and-a-half year follow-up period 16 of these 25 patients died, maximum survival time being 28.4 months. Survival varied from 9.2 to 28.4 months compared with a survival time of 2-8 months in untreated patients. In this case hypervascular tumours have a better prognosis than the rarer hypovascular tumours due to the improved deposition and activity of the chemotherapeutic agent inside the tumour itself.